A new study of more than two million older adults in Ontario has identified two dozen common drug combinations in which one medication’s side effect appears to trigger a second, unnecessary prescription. Researchers call the pattern a prescribing cascade, and the study links it to widely used drug classes including statins, iron supplements and dementia medications. The findings, published in The BMJ, are drawing attention from geriatric medicine specialists who say the pattern is often invisible to both patients and physicians. No recall or regulatory action is involved; the study is a call for closer scrutiny of routine prescribing habits.
How a Prescribing Cascade Takes Hold
A prescribing cascade begins when a drug’s side effect is mistaken for a new medical problem rather than a consequence of treatment already underway. A clinician who does not connect a new symptom to an existing prescription may respond by prescribing a second drug to manage what looks like a fresh condition. The result is a patient taking two medications where one might have sufficed, sometimes without either being reevaluated. Researchers note the connection is often missed because side effects do not always appear immediately; some can surface weeks, months or longer after a drug is started, making the link to the original prescription far less obvious than an early rash or allergic reaction would be.
The pattern tends to compound with age because older adults are more likely to be managing several chronic conditions at once, often under the care of multiple prescribers who may not see a complete, up-to-date medication list at every visit. A specialist treating one condition may have no visibility into a drug a primary care physician started months earlier, which makes it easier for a side effect to be treated as an isolated new complaint rather than connected back to an existing prescription.
Nearly 2.3 Million Ontario Health Records Behind the Analysis
The research team, led by geriatrician Paula Rochon of Sinai Health and the University of Toronto, examined administrative health data covering 2,297,942 community-dwelling adults aged 66 and older in Ontario, Canada. Roughly 54.3 percent of the group were women. Using a population-level retrospective cohort design, the researchers tracked prescribing sequences across the dataset to see how often one drug was followed, within a plausible time frame, by a second drug commonly used to treat that first drug’s known side effects.
From 65 Candidate Pairings to 24 Priority Cascades
The starting point for the analysis was a list of 65 potentially inappropriate prescribing cascades developed the previous year through a modified Delphi consensus process, in which 12 specialists in internal medicine, geriatric medicine and clinical pharmacology from eight countries rated and refined candidate drug pairings. Applying that list to the Ontario data, the researchers narrowed the group to 24 cascades that met three criteria: the initial medication had to be widely used, the follow-on prescription had to occur often enough to represent a meaningful pattern, and the timing between the two prescriptions had to be consistent with a genuine cascade rather than coincidence. The full methodology and results are detailed in the peer-reviewed study published in The BMJ.
Statins, Iron Supplements and Other Common Starting Points
Among the medications flagged as common starting points for a cascade were statins, iron supplements and central-nervous-system-active drugs, alongside several other widely prescribed classes. In each case, a known side effect of the first drug, such as muscle pain, gastrointestinal upset or sedation, can resemble a new health complaint closely enough that it prompts its own separate prescription. The Washington Post’s coverage of the findings noted that some of the flagged combinations involve drugs so commonly co-prescribed that neither patients nor pharmacists would necessarily flag the pairing as unusual.
The Pause Rochon’s Team Wants Built Into Routine Prescribing
The study’s authors frame their recommendation as a simple pause rather than a blanket restriction on any drug class. Before adding a new prescription, a clinician is encouraged to consider whether a patient’s new symptom could be a delayed side effect of a medication already in use, and if so, whether continuing both drugs together is still warranted or whether the original prescription should be adjusted instead. Because older adults are more likely to be managing several chronic conditions and multiple prescribers at once, the researchers argue that this kind of cross-check is easy to skip during a routine visit unless it is deliberately built into prescribing practice.
Why the Ontario Findings Extend Beyond One Province
Although the cohort is specific to Ontario, the drug classes involved, and the prescribing patterns that produce a cascade, are not unique to Canada’s health system. The University of Toronto’s summary of the research points out that the same medications dominate prescribing among older adults across most high-income health systems, meaning the 24 identified cascades are a plausible starting checklist for clinicians well outside Ontario. The researchers say the next step is testing whether flagging these specific combinations inside electronic prescribing systems reduces how often the cascades occur in practice.
The study adds to a broader movement within geriatric medicine known as deprescribing, in which physicians and pharmacists periodically review a patient’s full medication list with an eye toward removing drugs that may no longer be necessary or that may be working against each other. Proponents of that approach argue that identifying specific, well-documented cascades, rather than urging vague caution about polypharmacy in general, gives clinicians a concrete checklist they can act on during a routine medication review rather than an abstract principle that is easy to set aside under time pressure.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
